ISSN 1662-4009 (online)

ey0017.1-11 | Clinical Highlights | ESPEYB17

1.11. Endocrinology and adolescence: Dealing with transition in young patients with pituitary disorders

E Sbardella , C Pozza , AM Isidori , AB Grossman

To read the full abstract: Eur J Endocrinol. 2019 Oct;181(4):R155–R171. doi: 10.1530/EJE-19-0298. PMID: 31370006.Transition is described as the planned process of transferring care from pediatric to adult healthcare services. Recent recommendations by various medical associations underline that preparation of adolescents and their parents, consideration of the adolescent’s developmen...

ey0021.6-8 | New Clinical Insights into Klinefelter Syndrome | ESPEYB21

6.8. Testicular dysfunction in 47,XXY boys: when it all begins. a semilongitudinal study

C Pozza , F Sesti , M Tenuta , M Spaziani , C Tarantino , F Carlomagno , M Minnetti , R Pofi , R Paparella , A Lenzi , A Radicioni , AM Isidori , L Tarani , D Gianfrilli

Brief Summary: This longitudinal study provides an in-depth analysis of the clinical, endocrine, and testicular ultrasound (US) patterns in Klinefelter Syndrome (KS) from infancy through puberty and into adulthood, highlighting the progression of testicular degeneration in these patients.In this study, 155 KS patients with the classical 47,XXY karyotype, aged 7 months to 55 years, were prospectively evaluated at a single referral center following a stand...

ey0015.8-11 | Clinical Trials – New Treatments | ESPEYB15

8.11 Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial

AM Isidori , MA Venneri , C Graziadio , C Simeoli , D Fiore , V Hasenmajer , E Sbardella , D Gianfrilli , C Pozza , P Pasqualetti , S Morrone , A Santoni , F Naro , A Colao , R Pivonello , A. Lenzi

To read the full abstract: Lancet Diabetes Endocrinol. 2018; 6(3): 173-185Adrenal insufficiency (AI), caused by adrenal failure (primary) or hypothalamo-pituitary failure (secondary), has a prevalence of 250–450 per 1 million (16). AI is potentially life-threatening and requires lifelong glucocorticoid replacement therapy. Modified-release hydrocortisone preparations have bee...